The efficacy and safety of romiplostim in adult patients with chronic immune thrombocytopenia

Therapeutic Advances in Hematology

Volumn 3, Issue 5, 2012, Pages 291-298

  Cooper, Nichola ^a   Terrinoni, Ilaria ^a   Newland, Adrian ^b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

AMG 531; immune thrombocytopenia; romiplostim; thrombopoietin; thrombopoietin mimetic agents

Indexed keywords

ROMIPLOSTIM; THROMBOPOIETIN;

ARTHRALGIA; BLEEDING; CHRONIC DISEASE; DEEP VEIN THROMBOSIS; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; HEART INFARCTION; HUMAN; IMMUNE THROMBOCYTOPENIA; INSOMNIA; MEGAKARYOCYTE; MULTICENTER STUDY (TOPIC); MYALGIA; PAIN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOEMBOLISM;

EID: 84993760427     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620712453596     Document Type: Review

References (39)

1. Ballem P. Segal G. Stratton J. Gernsheimer T. Adamson J. Slichter S. (1987) Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 80: 33–40.
2. Bao W. Bussel J. Heck S. He W. Karpoff M. Boulad N. (2010) Improved regulatory T-cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood 116: 4639–4645.
3. Branehog I. Kutti J. Weinfeld A. (1974) Platelet survival and platelet production in idiopathic thrombocytopenic purpura (ITP). Br J Haematol 27: 127–143.
4. Branehog I. Weinfeld A. (1974) Platelet survival and platelet production in idiopathic thrombocytopenic purpura (ITP) before and during treatment with corticosteroids. Scand J Haematol 12: 69–79.
5. Broudy V. Lin N. (2004) AMG 531 stimulates megakaryopoiesis in vitro by binding to MPL. Cytokine 25: 52–60.
6. Bussel J. Kuter D. George J. McMillan R. Aledort L. Conklin G. (2006) AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 355: 1672–1681.
7. Bussel J. Rodeghiero F. Lyons R. (2011) Sustained hemostatic platelet counts in adults with immune thrombocytopenia (ITP) following cessation of treatment with the TPO receptor agonist romiplostim: report of 9 cases. Blood 118: 3281.
8. Chang M. Nakagawa P. Williams S. Schwartz M. Imfeld K. Buzby J. (2003) Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 102: 887–895.
9. de Sauvage F. Hass P. Spencer S. Malloy B. Gurney A. Spencer S. (1994) Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-MPL ligand. Nature 369: 533–538.
10. George J. Mathias S. Go R. Guo M. Henry D. Lyons R. (2009) Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 144: 409–415.
11. George J. Woolf S. Raskob G. Wasser J. Aledort L. Ballem P. (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88: 3–40.
12. Hartley C. McElroy T. Molineux G. (2005) The novel thrombopoietic agent AMG 531 is effective in pre-clinical models of chemo / radiotherapy induced thrombocytopenia. Proc Am Assoc Cancer Res 46: 1233.
13. Kelton J. (1982) Autoimmune platelet destruction: idiopathic thrombocytopenic purpura. Semin Thromb Hemost 8: 83–104.
14. Kuter D. Bain B. Mufti G. Bagg A. Hasserjian R. (2007) Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 139: 351–362.
15. Kuter D. Beeler D. Rosenberg R. (1994) The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 91: 11104–11108.
16. Kuter D. Bussel J. Lyons R. Pullarkat V. Gernsheimer T. Senecal F. (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371: 395–403.
17. Kuter D. Bussel J. Newland A. Wasser J. Lyons R. George J. (2010 a) Long term efficacy and safety of romiplostim treatment of adult patients with chronic immune thrombocytopenia (ITP); final report. Blood 116: 68.
18. Kuter D. Bussel J. Newland A. Baker R. Lyons R. Wasser J. (2012 a) Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia (ITP): safety and efficacy. Submitted.
19. Kuter D. Mathias S. Rummel M. Mandanas R. Giagounidis A. Wang X. (2012 b) Health-related quality of life in non-splenectomized immune thrombocytopenia (ITP) patients receiving romiplostim or medical standard of care. Am J Hematol 87: 558–561.
20. Kuter D. Rummel M. Boccia R. Macik B. Pabinger I. Selleslag D. (2010 b) Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 363: 1889–1899.
21. Li J. Yang C. Xia Y. Bertino A. Glaspy J. Roberts M. (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98: 3241–3248.
22. Mathias S. Gao S. Miller K. Cella D. Snyder C. Turner R. (2008) Impact of chronic immune thrombocytopenic purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health Qual Life Outcomes 6: 13.
23. Newland A. (2009) Romiplostim: a breakthrough treatment for the management of immune thrombocytopenic purpura. Eur J Haematol 82(Suppl. 71): 20–25.
24. Newland A. Caulier M. Kappers-Klunne M. Schipperus M. Lefrere F. Zwaginga J. (2006) An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 135: 547–553.
25. Newland A. Cervinék L. Eggermann J. Lefrere F. Kreuzbauer G. (2011) Sustained hemostatic platelet counts in adult patients with primary immune thrombocytopenia (ITP) following cessation of romiplostim – four European case studies. Haematologica 96: 98.
26. Olsson B. Andersson P. Jernas M. Jacobsson S. Carlsson B. Carlsson L. (2003) T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 9: 1123–1124.
27. Portielje J. Westendorp R. Kluin-Nelemans H. Brand A. (2001) Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97: 2549–2554.
28. Provan D. Butler T. Evangelista M. Amadori S. Newland A. Stasi R. (2007) Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 92: 1695–1698.
29. Provan D. Newland A. (2007) Romiplostim. Drugs Future 32: 781–787.
30. Provan D. Newland A. Norfolk D. Bolton-Maggs P. Lilleyman J. Greer I. (2003) Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 120: 574–596.
31. Pullarkat V. Gernsheimer T. Wasser J. Newland A. Guthrie T. Jr de Wolf J. (2009) Quantifying the reduction in immunoglobulin use over time in patients with chronic immune thrombocytopenic purpura receiving romiplostim (AMG 531). Am J Hematol 84: 538–540.
32. Rodeghiero F. Stasi R. Gernsheimer T. Michel M. Provan D. Arnold D. (2008) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children: report from an international working group. Blood 113: 2386–2393.
33. Sanz M. Aledort L. Mathias S. Wang X. Isitt J. (2011) Analysis of EQ-5D scores from two phase III clinical trials of romiplostim in the treatment of immune thrombocytopenia. Value Health 14: 90–96.
34. Sarpatwari A. Bennett D. Logie J. Shukla A. Beach K. Newland A. (2010) Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 95: 1167–1175.
35. Shirasugi Y. Ando K. Miyazaki K. (2011) Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double blind randomised phase III clinical trial. Int J Hematol 94: 71–72.
36. Snyder C. Mathias S. Cella D. Isitt J. Wu A. Young J. (2008) Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin 24: 2767–2776.
37. Stasi R. Stipa E. Masi M. Cecconi M. Scimo M. Oliva F. (1995) Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 98: 436–442.
38. Tarantino M. Henry D. Go R. Lefrere F. Lichtin A. Terebelo H. (2007) Health-related quality of life (HRQoL) in patients with chronic immune thrombocytopenic purpura (ITP): interim results from an open-label study of AMG 531. Blood (ASH Annual Meeting Abstracts) 110: 1324.
39. Wang B. Nichol J. Sullivan J. (2004) Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 76: 628–638.